Amoéba Secures French Market Authorization for Axpera
Amoéba announced on Tuesday that it has obtained market authorization (MA) in France for its biofungicide Axpera, granted by ANSES. This first permanent authorization paves the way for other European member states to finalize their own authorization procedures in the coming weeks and months.
Authorization Covering Vineyards and Vegetable Crops
Axpera is authorized as a fungicidal product that works by inhibiting the germination of fungal spores. The product covers multiple uses in vineyards and vegetable crops, particularly against downy mildew, powdery mildew, gray mold, and scab. It can be used preventatively, alone or in combination with other approved fungicides.
Favorable Usage Conditions and Exemption from Maximum Residue Limits
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Axpera enjoys particularly favorable usage conditions: a re-entry interval of 6 hours in open fields and 8 hours under cover, a pre-harvest interval of 1 day, and reduced safety distances (5 meters from aquatic surfaces, 3 meters from people). The active substance of the product is on the list of substances exempt from maximum residue limits, eliminating the constraints of residue analysis on treated crops. The product is authorized for use in both conventional and organic agriculture and must be included on the French list of biocontrol products.
An Authorization Accelerating Expansion in Europe and Beyond
The authorization in France, which has taken on the role of rapporteur member state for the zone, accelerates authorizations in other targeted European countries. Amoéba markets the product in partnership with Koppert, under the brand names Tiagan for vineyards and Yazu for vegetable crops. This first permanent authorization, valid for 15 years and renewable, facilitates future geographic expansions and the broadening of uses, while the product has already been approved in the United States in 2025.
Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
Expected revenue: 1,5 millions d'euros
Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.